Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) (TASE:CFBI) CEO Pnina Fishman tells Proactive the Petach Tikva, Israel-based biotechnology company is looking forward to completing enrollment of its Phase IIl study to treat psoriasis.
Fishman says while its lead drug candidate, Piclidenoson, has similar efficacy to the current approved drug on the market to treat psoriasis, it has a 'much better safety profile.' She expects to report data from the clinical trial before the end of 2021.